ViroPharma Shares Plunged: What You Need to Know (VPHM)

ViroPharma Shares Plunged: What You Need to Know

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: ViroPharma Inc. (Nasdaq: VPHM ) shares fell 10% on Friday after the FDA declined expansion plans for Cinryze.

So what: The FDA declined industrial-scale manufacturing of Cinryze, which treats a fatal genetic disorder called hereditary angioedema. Regulators are looking for more information after observations at pre-approval inspections and a review of the process.

Now what: The company still plans to move forward with higher production assuming risk moving forward. After pummeling the stock 17% in pre-market trading, the stock is up significantly on the day. The risks seem minimal going forward, so barring further setbacks I view this dip as a short-term buying opportunity.

Interested in more info on ViroPharma? Add it to your watchlist here by clicking here.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.

Try any of our Foolish newsletter services free for 30 days. True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.